Manager's transaction related to
____________________________________________
Person subject to the notification requirement
Position: Other senior manager
Issuer:
LEI: 743700JJO2NU8LBS1592
Notification type: INITIAL NOTIFICATION
Reference number: 743700JJO2NU8LBS1592_20200830183117_2
____________________________________________
Transaction date: 2020-08-29
Venue not applicable
Instrument type: SHARE
ISIN: FI4000330972
Nature of the transaction: EXERCISE OF A STOCK OPTION
(X) Linked to stock option programme
Transaction details
(1): Volume: 10,000 Unit price:
Aggregated transactions
(1): Volume: 10,000 Volume weighted average price:
For further information, please contact:
peter.hanninen@nanoform.com / +358 50 353 0408
For investor relations queries, please contact:
hvh@nanoform.com / +46 7686 650 11
Certified Adviser:
About Nanoform
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nanoforming services. The Company's patented and scalable Controlled Expansion of Supercritical Solutions (CESS[®)] technology produces nanoformed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Nanoform's unique technology provides novel opportunities in many value-enhancing drug delivery applications. Nanoform's share is listed on the Premier-segment of Nasdaq First North Growth Market in
For more information please visit http://www.nanoform.com
https://news.cision.com/nanoform/r/nanoform-finland-plc---manager-s-transactions---goncalo-andrade,c3187606
https://mb.cision.com/Main/18905/3187606/1301413.pdf
(c) 2020 Cision. All rights reserved., source